Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
External, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
How managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.